Biotech News
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
ir.newamsterdampharma.com2026-05-06 14:54 EST
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient enrolled in RUBENS Phase 3 trial of obicetrapib and obicetrapib/ezetimibe fixed dose